HomeCompareRHHBF vs EQR

RHHBF vs EQR: Dividend Comparison 2026

RHHBF yields 2.28% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $19.1K in total portfolio value
10 years
RHHBF
RHHBF
● Live price
2.28%
Share price
$410.32
Annual div
$9.37
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.7K
Annual income
$1,518.26
Full RHHBF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — RHHBF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRHHBFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RHHBF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RHHBF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RHHBF
Annual income on $10K today (after 15% tax)
$194.20/yr
After 10yr DRIP, annual income (after tax)
$1,290.52/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $3,363.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RHHBF + EQR for your $10,000?

RHHBF: 50%EQR: 50%
100% EQR50/50100% RHHBF
Portfolio after 10yr
$38.3K
Annual income
$3,496.93/yr
Blended yield
9.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RHHBF
Analyst Ratings
3
Buy
5
Hold
1
Sell
Consensus: Hold
Altman Z
5.3
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RHHBF buys
0
EQR buys
0
No recent congressional trades found for RHHBF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRHHBFEQR
Forward yield2.28%5.87%
Annual dividend / share$9.37$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17%15.8%
Portfolio after 10y$28.7K$47.8K
Annual income after 10y$1,518.26$5,475.61
Total dividends collected$7.3K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: RHHBF vs EQR ($10,000, DRIP)

YearRHHBF PortfolioRHHBF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,967$267.32$11,380$679.82$413.00EQR
2$12,056$320.57$13,014$837.25$958.00EQR
3$13,285$385.32$14,961$1,036.20$1.7KEQR
4$14,679$464.29$17,297$1,289.22$2.6KEQR
5$16,268$560.96$20,121$1,613.15$3.9KEQR
6$18,086$679.77$23,561$2,030.84$5.5KEQR
7$20,178$826.39$27,783$2,573.54$7.6KEQR
8$22,599$1,008.16$33,013$3,284.39$10.4KEQR
9$25,416$1,234.62$39,547$4,223.51$14.1KEQR
10$28,713$1,518.26$47,791$5,475.61$19.1KEQR

RHHBF vs EQR: Complete Analysis 2026

RHHBFStock

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.

Full RHHBF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RHHBF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RHHBF vs SCHDRHHBF vs JEPIRHHBF vs ORHHBF vs KORHHBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.